Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
ADAM17 is upregulated in many cancers and in turn activates signaling pathways, including EGFR/ErbB, as well as those underlying resistance to targeted anti-EGFR therapies. Due to its central role in oncogenic pathways and drug resistance mechanisms, specific and efficacious monoclonal antibodies ag...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Elsevier
2022
|
Subjects: | |
Online Access: | https://doaj.org/article/0c1537a2f183403bbaf393d83c36b312 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|